依维莫司初治罕见晚期血管肉瘤的临床疗效及安全性分析

李智勇; 张秀萍; 张世龙; 许建芳; 王志明; 周宇红

doi:10.12025/j.issn.1008-6358.2019.20190041

依维莫司初治罕见晚期血管肉瘤的临床疗效及安全性分析

1.
复旦大学附属中山医院厦门医院肿瘤内科，厦门 361015
2.
复旦大学附属中山医院血液科，上海 200032
3.
复旦大学附属中山医院厦门医院病理科，厦门 361015
4.
复旦大学附属中山医院肿瘤内科, 上海 200032

计量
- 文章访问数: 1806
- HTML全文浏览量: 0
- PDF下载量: 990
出版历程
- 收稿日期: 2019-01-08
- 修回日期: 2019-04-16
- 刊出日期: 2019-06-24

Efficacy and safety of everolimus in treatment of advanced angiosarcoma

摘要

摘要: 目的：探讨mTOR抑制剂依维莫司治疗晚期血管肉瘤的临床疗效及安全性。方法：收集2013年11月至2018年9月采用依维莫司初治的5例晚期血管肉瘤患者的临床资料，观察并分析疗效与不良反应情况。结果：4例晚期血管肉瘤患者经依维莫司治疗数天后症状缓解，病灶缩小；1例阿帕替尼耐药的晚期血管肉瘤患者对依维莫司无反应，病情进展。依维莫司治疗不良反应主要为口腔溃疡，其中2例患者2级、3例患者1级。结论：依维莫司初治晚期血管肉瘤起效快，疗效较好，不良反应可控，值得进一步研究
- 血管肉瘤 /
- 依维莫司 /
- 初治 /
- 不良反应
Abstract: Objective：To investigate the efficacy and safety of mTOR inhibitor everolimus in the treatment of advanced angiosarcoma. Methods：Clinical data of 5 patients with advanced angiosarcoma initially treated with everolimus from November 2013 to September 2018 were collected to observe the efficacy and adverse reactions. Results：The symptoms of 4 patients with advanced angiosarcoma were relieved and the lesions narrowed within a few days after the treatment of everolimus. One patient with advanced angiosarcoma who was resistant to apatinib continued to progress. The main adverse effects of everolimus were oral ulcers, of which 2 cases were grade 2 and 3 cases were grade 1. Conclusions：Everolimus is effective in the treatment of advanced angiosarcoma with rapid onset of action and controllable adverse effects.
- angiosarcoma /
- everolimus /
- initial treatment /
- adverse effects

HTML全文

参考文献(25)

[1]	Aust MR, Olsen KD, Lewis JE, et al. Angiosarcomas of the head and neck: clinical and pathologic characteristics[J]. The Annals of otology, rhinology, and laryngology. 1997, 106(11):943-51.
[2]	Ogawa K, Takahashi K, Asato Y, et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients[J]. Br J Radiol. 2012, 85(1019):e1127-33.
[3]	Chow TL, Kwan WW, Kwan CK. Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong[J]. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2018, 24(1):25-31.
[4]	Shin JY, Roh SG, Lee NH, et al. Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis[J]. Head neck. 2017, 39(2):380-6.
[5]	Hwang K, Kim MY, Lee SH. Recommendations for therapeutic decisions of angiosarcoma of the scalp and face[J]. The Journal of craniofacial surgery. 2015, 26(3):e253-6.。
[6]	Kato S. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor][J]. Nihon rinsho Japanese journal of clinical medicine. 2015, 73(8):1398-402.
[7]	Pusceddu S, Verzoni E, Prinzi N, et al. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential[J]. Therapeutic advances in medical oncology. 2017, 9(3):183-8.
[8]	Yoo C, Lee J, Rha SY, et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide[J]. Investigational new drugs. 2013, 31(6):1602-8.
[9]	ElNaggar AC, Hays JL, Chen JL. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series[J]. PloS one. 2016,11(6):e0156985.
[10]	Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma[J]. Annals of surgical oncology. 2009, 16(9):2502-9.
[11]	Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma[J]. The oncologist. 2007, 12(8):1007-18.
[12]	Burris HA, 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway[J]. Cancer chemotherapy and pharmacology. 2013, 71(4):829-42.
[13]	Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy[J]. Current medicinal chemistry Anti-cancer agents. 2005, 5(6):575-89.
[14]	Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment[J]. Current opinion in investigational drugs. 2006, 7(6):501-12.
[15]	Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab[J]. JAMA oncology. 2017, 3(4):509-15.
[16]	Vincenzi B, Frezza AM, Santini D, et al. New therapies in soft tissue sarcoma[J]. Expert opinion on emerging drugs. 2010, 15(2):237-48.
[17]	Strimpakos AS, Karapanagiotou EM, Saif MW, et al. The role of mTOR in the management of solid tumors: an overview[J]. Cancer treatment reviews. 2009 , 35(2):148-59.
[18]	Young RJ, Woll PJ, Staton CA, et al. Vascular-targeted agents for the treatment of angiosarcoma. Cancer Chemother Pharmacol, 2014, 73(2):259-70.
[19]	Zhang SL, Liang L, Ji Y, et al. The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review. Oncotarget, 2017, 8 (55), 95023-95029.
[20]	Tran Minh M, Mazzola A, Perdigao F, et al. Primary hepatic angiosarcoma and liver transplantation: Radiological, surgical, histological findings and clinical outcome. Clin Res Hepatol Gastroenterol. 2018, 42(1):17-23.
[21]	Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer, 2009, 100(2): 315–321.
[22]	Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy[J]. Hematology/oncology clinics of North America. 2012, 26(3):483-505.
[23]	Delbaldo C, Albert S, Dreyer C, et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors[J]. Targeted oncology. 2011, 6(2):119-24.
[24]	Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy[J]. The Journal of clinical investigation. 2011, 121(4):1231-41.
[25]	Li F, Wang Q, Xiong X, et al. Expression of 4E-BP1 and phospho-4E-BP1 correlates with the prognosis of patients with clear cell renal carcinoma[J]. Cancer management and research. 2018,10:1553-63.